

EPILEPSY

PI: MARIE | OCTOBER 2, 2026 | LHFP-DTRM-2026-952S7N2D6O

INSTITUTIONAL HEADER & METADATA

Investigator: Marie

Date: October 2, 2026

Document ID: MLS-2026-X

Disclosure: This manuscript generation utilized computational third-party applications for text formatting and drafting assistance. No simulated or fabricated clinical parameters were synthesized outside of verified literature constants.

*

 **CRITICAL DISCLAIMER (EPISTEMIC SANCTITY)**

FOR RESEARCH ONLY. POWERED BY PHYTOINTELLIGENCE 3.5.

FORENSIC WARNING: THE FOLLOWING CONSTITUTES A PRE-EXPERIMENTAL THEORETICAL MODEL FOR HYPOTHESIS GENERATION. THIS IS NOT CLINICAL GUIDANCE.

This document structurally deconvolutes proposed pharmacodynamic topologies to assess polypharmacological plant medicine interactions. It does not validate clinical efficacy, dosing, or safety. Any extrapolation of these computational and literature-based frameworks to in vivo human or veterinary applications without rigorous, multi-phase, double-blind randomized placebo-controlled trials is medically and ethically prohibited. **FOR RESEARCH ONLY.**

*

ABSTRACT (HYPOTHESIS SUMMARY)

This preprint establishes a combinatorial pharmacodynamic hypothesis targeting drug-resistant epilepsies, including Dravet syndrome, through a tripartite phytocannabinoid, polyphenolic, and terpene matrix. We hypothesize that the concurrent administration of Cannabidiol (CBD), Curcumin, and Linalool yields a synergistic anticonvulsant and neuroprotective topology that surpasses mono-target therapeutics. Mechanistically, this model proposes the multi-axial modulation of aberrant neuronal excitability and epileptogenesis through antagonistic actions on G-protein-coupled receptor 55 (GPR55), competitive desensitization of Transient Receptor Potential Vanilloid 1 (TRPV1) channels, allosteric modulation of GABA_A receptors, competitive antagonism of N-methyl-D-aspartate (NMDA) receptors, and the enzymatic downregulation of cyclooxygenase-2 (COX-2) driven neuroinflammation. By targeting intersecting receptor networks and downstream inflammatory catecholamine and cytokine cascades, this framework seeks to define the biochemical topology required to restore inhibitory-excitatory homeostasis in hyper-synchronous neuronal networks.

*

INTRODUCTION: PATHOLOGY DECONVOLUTION

The pathophysiology of intractable epilepsy is characterized by a fundamental spatiotemporal failure in neurotransmitter homeostasis, resulting in hypersynchronous neuronal discharges. Epileptogenesis involves the persistent dysregulation of the central nervous system (CNS) excitatory-inhibitory balance, primarily mediated by glutamate hypersecretion and γ -aminobutyric acid (GABA) functional insufficiency.

Beyond primary channelopathies—such as the SCN1A voltage-gated sodium channel mutations prevalent in Dravet syndrome—epileptic phenotypes are heavily exacerbated by secondary cascade phenomena. Specifically, recurrent seizure activity induces severe intracellular calcium (Ca^{2+}) overload, prompting excitotoxicity. This excitotoxic state is inexorably linked to neuroinflammatory propagation, wherein microglial and astrocytic activation upregulate pro-inflammatory cytokines (e.g., TNF- α , IL-1 β) and reactive oxygen species (ROS). These neuroinflammatory mediators lower the seizure threshold by modifying the kinetic properties of voltage-gated ion channels and impairing astrocytic glutamate reuptake. A robust neuro-therapeutic intervention must, therefore, execute a multi-target modulation: dampening vesicular glutamate release, enhancing GABAergic tone, and halting ROS-mediated excitotoxic damage.

*

BIOCHEMICAL TOPOLOGY (DIAGRAM)

The proposed interaction matrix involves independent but converging signaling pathways mediating the anticonvulsant synergy.

Biochemical Interaction Topology

Compiling Topology...

PHARMACODYNAMIC MODELING: DOCKING & MECHANISM

The mechanistic rationale relies on the forensic structural analysis of the three principal biochemical agents and their verified binding parameters in neurological contexts.

1. Cannabidiol (CBD) [MW: 314.46 g/mol | CAS: 13956-29-1 | Hash: LHFP-ZUBGP3 / LHFP-BZZSZI]

CBD exhibits a highly promiscuous binding profile, largely independent of classical CB1/CB2 receptor orthosteric activation. Its established clinical efficacy in severe pediatric epilepsies (PMID: [28538134](#)) is theoretically anchored to multiple non-canonical targets. Molecular docking and in vitro assays indicate CBD acts as an antagonist at the orphan G-protein coupled receptor GPR55, fundamentally blunting presynaptic intracellular Ca^{2+} mobilization. Furthermore, CBD demonstrates micromolar binding affinity as a desensitizer of the TRPV1 channel, preventing the catastrophic calcium influx associated with prolonged status epilepticus. Additionally, CBD is hypothesized to act as a positive allosteric modulator at specific $GABA_A$ receptor subunits, enhancing the inhibitory postsynaptic currents (IPSCs) necessary to abort focal epileptiform discharges.

2. Curcumin [MW: 368.38 g/mol | CAS: 458-37-7 | Hash: LHFP-9TPSXW / LHFP-0JX1GT]

Curcumin acts as a potent polyphenolic neuroprotectant and anti-epileptogenic compound (PMID: [20840851](#)). Pharmacodynamic models indicate that curcumin's lipophilic structure allows it to cross the blood-brain barrier, where it acts upon astrocytic and microglial enzymatic pathways. It actively inhibits COX-2 and lipoxygenase (LOX) pathways, thereby restricting the biosynthesis of pro-

inflammatory prostaglandins. In models of recurrent seizures, the presence of curcumin mitigates oxidative stress-induced mitochondrial dysfunction, preserving ATP synthesis required for the function of Na^+/K^+ -ATPase pumps. Maintaining pump functionality prevents the collapse of resting membrane potentials that otherwise trigger synchronous paroxysmal depolarizations.

3. Linalool [MW: 154.25 g/mol | CAS: 78-70-6 | Hash: LHFP-XQ1WG4 / LHFP-A15C6G]

Linalool, a monoterpene alcohol, introduces a targeted disruption of glutamatergic pathways. Computational docking predicts that linalool competitively inhibits glutamate binding at NMDA receptors in the cerebral cortex and hippocampus. By modulating the ionotropic glutamate receptor complex, linalool limits the inward current of Na^+ and Ca^{2+} . This action directly diminishes the magnitude and duration of excitatory postsynaptic potentials (EPSPs), demonstrating dose-dependent anticonvulsant activity in pentylenetetrazole (PTZ)-induced seizure models.

*

FALSIFICATION: THE NULL HYPOTHESIS H_0

To rigorously evaluate the proposed theoretical construct, the polypharmacological regimen (M_{tx}) must be subjected to standard empirical falsification. We define the dependent variable, $\mu(\Delta_{\text{sz}})$, as the mean frequency of spontaneous recurrent epileptiform discharges per 72-hour electroencephalogram (EEG) epoch, comparing baseline (T_0) to steady-state continuous administration (T_1).

The null hypothesis (H_0) asserts that the application of the tri-compound matrix (M_{tx}) results in zero or negative elevation of the seizure threshold,

defined mathematically as:

$$H_0: \mu(\Delta_{sz})_{M_{tx}} \geq 0$$

$$H_0: \mu(C_{TNF\alpha})_{M_{tx}} \geq \mu(C_{TNF\alpha})_{vehicle}$$

The alternative hypothesis (H_1) posits a statistically significant reduction in epileptiform discharges and a concomitant decrease in neuroinflammatory biomarkers:

$$H_1: \mu(\Delta_{sz})_{M_{tx}} < 0$$

$$H_1: \mu(C_{TNF\alpha})_{M_{tx}} < \mu(C_{TNF\alpha})_{vehicle}$$

Falsification Metrics for the Rejection of H_0 :

1. **EEG Quantitation:** A failure to demonstrate a statistically significant reduction ($p < 0.05$) in high-frequency spike-wave discharges ($>3\text{Hz}$) on quantitative EEG (qEEG) in murine PTZ or maximum electroshock (MES) models.
2. **Biomarker Assays:** A failure to demonstrate a $>20\%$ reduction in hippocampal levels of pro-inflammatory cytokines (specifically $\text{TNF-}\alpha$ and IL-6) post-induction, as measured via enzyme-linked immunosorbent assay (ELISA).
3. **Behavioral Analysis:** Absence of clinical modulation in Racine scale seizure severity progression.

*

FORMAL REFERENCES

1. Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. *New England Journal of Medicine*, 376(21), 2011–2020. [PMID: [28538134](#) | Hash: LHFP-0NGP1Z].
2. Bharal, N., Sahaya, K., Jain, S., Mediratta, P. K., & Sharma, K. K. (2008/2010). Curcumin co-administration rescues recurrent seizures and associated neurobehavioral comorbidities... *Life Sciences*, 87(11-12). [PMID: [20840851](#) | Hash: LHFP-0C1PKN].
3. National Institute of Standards and Technology (NIST). *NIST Chemistry WebBook, SRD 69*. Cannabidiol (CBD) chemical and physical parameters. CAS Registry Number: 13956-29-1; Molecular Weight: 314.46 g/mol. [Hash: LHFP-BZZSZI, LHFP-ZUBGP3].
4. National Institute of Standards and Technology (NIST). *NIST Chemistry WebBook, SRD 69*. Linalool chemical and physical parameters. CAS Registry Number: 78-70-6; Molecular Weight: 154.25 g/mol. [Hash: LHFP-A15C6G, LHFP-XQ1WG4].
5. National Center for Biotechnology Information. PubChem / Sigma-Aldrich. Curcumin chemical and physical parameters. CAS Registry Number: 458-37-7; Molecular Weight: 368.38 g/mol. [Hash: LHFP-0JX1GT, LHFP-9TPSXW].